No abstract

Background: COVID-19 is a public health emergency of international concern. Its incidence rates and mortality are very high; however, so far, an effective drug treatment remains unknown. Based on the role of convalescent plasma therapy in previously identified viral pneumonias, patients with severe COVID-19 have been given this therapy. This systematic review and meta-analysis aimed to summarize the clinical evidence regarding the efficacy and safety of convalescent plasma therapy in the treatment of severe COVID-19. Methods: PubMed, Embase, Ovid, China Knowledge Network, China Biomedical, VIP Chinese Sci-tech Journal, Wanfang Database, and the International Clinical Trials Registry Platform were searched up to 21 June 2020, to identify clinical studies and registered trials on the use of convalescent plasma in the treatment of critically ill patients with COVID-19. Stata 13.0 was used to perform Meta-analysis. All records were screened as per the protocol eligibility criteria. Results: Nineteen clinical reports regarding convalescent plasma in the treatment of severe COVID-19 were included. Through systematic analysis, convalescent plasma was found to yield some efficacy on severe COVID-19 and had almost no obvious adverse reactions. Conclusion: Convalescent plasma therapy seems to yield some efficacy among patients with severe COVID-19 and almost no obvious adverse reactions were found. However, at present, the clinical evidence is insufficient, and there is an urgent need for support from high-quality clinical trial data.

No abstract

Objective: To systematically evaluate the efficacy and safety of lopinavir/ritonavir (LPV/r) in the treatment of COVID-19. Methods: PubMed, Embase, Ovid, CNKI, CBM, Wanfang, and VIP databases were searched to obtain the clinical studies of LPV/r in the treatment of COVID-19 from December 2019 to July 2020. The literatures were screened according to the inclusion and exclusion criteria. Their qualities were evaluated according to the Newcastle-Ottawa Scale (NOS) and RevMan 5.3 software was used for meta-analysis. Results: A total of 688 patients were included in five studies, involving China and France. Compared with patients in the control group, who was only treated with routine treatment, there were no significant differences of the 7-day nucleic acid negative conversion rate and 14-day nucleic acid negative conversion rate in the treatment group. However, the use of LPV/r increased the incidence of adverse reactions in the treatment group compared to the control group. Conclusion: There is no available evidence to support the use of Lopinavir/ritonavir in the treatment of COVID-19.

Objective: To explore the characteristics and influencing factors of coagulation indexes in patients with pulmonary infection sepsis. Methods: 104 patients in Shaanxi Provincial Hospital of Chinese Medicine from January 2015 to April 2021 were collected and divided into case group (52 cases) and control group (52 cases). The general data and coagulation indexes of the two groups were statistically analyzed. The difference was statistically significant (P < 0.05). Binary logistic regression analysis was used. Results: The indexes of age PT, APTT, TT, FDP, D-Dimer, INR and PLT in the control group were significantly higher than those in the control group (P < 0.05); There was no significant difference in FIB-C (P > 0.05); Binary logistic regression analysis showed that D-Dimer and PLT were the risk factors of pulmonary infection sepsis (OR > 1, P < 0.05). Conclusion: FDP and D-Dimer are risk factors for the development of pneumonia into sepsis.